KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Investing Activities: 2018-2025

Historic Cash from Investing Activities for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to -$18.4 million.

  • Castle Biosciences' Cash from Investing Activities fell 24.34% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.4 million, marking a year-over-year increase of 0.24%. This contributed to the annual value of -$50.1 million for FY2024, which is 209.81% down from last year.
  • As of Q3 2025, Castle Biosciences' Cash from Investing Activities stood at -$18.4 million, which was up 35.20% from -$28.4 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Cash from Investing Activities peaked at $16.6 million during Q1 2023, and registered a low of -$134.2 million during Q3 2022.
  • Over the past 3 years, Castle Biosciences' median Cash from Investing Activities value was -$15.4 million (recorded in 2023), while the average stood at -$12.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 14,434.13% in 2022, then surged by 4,225.37% in 2023.
  • Quarterly analysis of 5 years shows Castle Biosciences' Cash from Investing Activities stood at -$30.9 million in 2021, then surged by 85.49% to -$4.5 million in 2022, then crashed by 71.17% to -$7.7 million in 2023, then surged by 175.21% to $5.8 million in 2024, then fell by 24.34% to -$18.4 million in 2025.
  • Its Cash from Investing Activities stands at -$18.4 million for Q3 2025, versus -$28.4 million for Q2 2025 and -$22.4 million for Q1 2025.